Clinical trial

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT01107626

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Bevacizumab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Disodium Heptahydrate Normalized identity: pemetrexed disodium heptahydrateView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-10-25

PhasePHASE3

Conditions

Lung Cancerverified · MONDO: lung cancer

Interventions

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

BevacizumabBIOLOGICAL

Pemetrexed Disodium HeptahydrateDRUG · verified · RxNorm: pemetrexed disodium heptahydrate

Sponsors & collaborators

ECOG-ACRIN Cancer Research Grouplead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

ChicagoIllinois, United States8 DenverColorado, United States7 ToledoOhio, United States6 Des MoinesIowa, United States6 Green BayWisconsin, United States6 PhiladelphiaPennsylvania, United States5 OmahaNebraska, United States5 New OrleansLouisiana, United States5 GreenvilleSouth Carolina, United States5 TacomaWashington, United States5 DaytonOhio, United States5 ClevelandOhio, United States4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01107626 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.